A review of why and how we may use β-blockers in congestive heart failure

Chest

Volumn 113, Issue 3, 1998, Pages 800-808

  Constant, Jules ^a  

^a UNIVERSITY AT BUFFALO   (United States)

Author keywords

ACE inhibitors; Bucindolol; Carvedilol; Congestive heart failure; Metoprolol; Upregulation; blockers

Indexed keywords

ACEBUTOLOL; ADRENALIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; BUCINDOLOL; CARVEDILOL; DIGITALIS; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDRALAZINE; METOPROLOL; NITRATE; PLACEBO; PRAZOSIN; PROPRANOLOL; TIMOLOL;

BETA ADRENERGIC RECEPTOR BLOCKING; CONGESTIVE HEART FAILURE; DOSE RESPONSE; DRUG MECHANISM; DRUG MIXTURE; DRUG SELECTIVITY; HEART DILATATION; HEART LEFT VENTRICLE MASS; HEART MUSCLE FIBROSIS; HEART MUSCLE ISCHEMIA; HEART VENTRICLE FIBRILLATION; HUMAN; MORTALITY; PRIORITY JOURNAL; REVIEW; SUDDEN DEATH;

EID: 0031912652     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.113.3.800     Document Type: Review

References (66)

1. Waagstein F, Hjalmarson A, Varnauskas E, et al. Effect of chronic beta-adrenergic blockade in congestive cardiomyopathy. Hr Heart J 1975; 37:1022-36
2. Currie PJ, Kelly MJ, Mckenzie A, et al. Oral beta-adrenergic blockade with metoprolol in chronic severe dilated cardiomyopathy, J Am Coll Cardiol 1984; 3:203-9
3. Ikram H, Fitzpatrick D. Double-blind trial of chronic oral beta blockade in congestive cardiomyopathy. Lancet 1981; 2:490-92
4. Swedberg K, Waagstein F, Hjalmarson A, et al. Beneficial effects of long-term beta blockade in congestive cardiomyopatliy. Br Heart J 1980; 44:117-33
5. Fowler MB, Bristow MR, Laser JA. Beta blocker therapy in severe heart failure [abstract], Cirenlation 1984; 70(suppl II):II-112
6. Engelmeier RS, O'Connell JB, Walsh H, et al. Improvement in symptoms and exercise tolerance by metoprolol in patients with dilated cardiomyopathy: a double-blind, randomized, placebo-controlled trial. Circulation 1985; 72:536-46
7. Engelmeier B, O'Connel JB, Rad N, et al. Metoprolol in dilated cardiomyopathy: long-term follow up [abstract]. Circulation 1986; 74(suppl II):II-309
8. Heilbrunn SM, Shah P, Bristow MR, et al. Increased beta-receptor density and improved hemodynamic response to catecholamine stimulation during long-term metoprolol therapy in heart failure from dilated cardiomyopathy. Circulation 1989; 79:483-90
9. Brodsky MA, Allen BJ, Bessen M, et al. Beta blocker therapy in patients with ventricular tachyarrhythmias in the setting of left ventricular dysfunction. Am Heart 1988; 115:799-807
10. Waagstein F, Bristow MR, Swedberg K, et al. Beneficial effect of metoprolol in idiopathic dilated cardiomyopathy. Lancet 1993; 342:1441-46
11. Rahman MA, Hara K, Senn BM, et al. Reductions in muscle sympathetic nerve activity after chronic beta-blockade for dilated cardiomyopathy [abstract]. Circulation 1993; 88(suppl):I-415
12. Eichhorn KJ, Heesch CM, Barnett JH. Effect of metoprolol on myocardial function and energetics in patients with nonischemic dilated cardiomyopathy. J Am Coll Cardiol 1994; 24:1310-20
13. McDonald KM, Rector T, Carlyle PF, et al. Angiotensin-couverting enzyme inhibition and beta-adrenoceptor blockade regress established ventricular remodeling in a canine model of discrete myocardial damage. J Am Coll Cardiol 1994; 24:1762-68
14. Hall SA, Cigarroa CC, Marcous D, et al. Time course of improvement in left ventricular function, mass and geometry in patients with congestive heart failure treated with beta-adrenergic blockade. J Am Coll Cardiol 1995; 25;1154-61
15. The Cardiac Insufficiency Bisoprolol Study (CIBIS). A randomized trial of beta-blockade in heart failure. Circulation 1994; 90;1765-73
16. Swedberg K, Waagstein F, Hjalmarson A, et al. Prolongation of survival in congestive cardiomyopathy by beta receptor blockade. Lancet 1979; 1:1374-76
17. Anderson JL, Lutz JB, Gilbert KM, et al. A randomized trial of low-dose beta blockade therapy for idiopathic dilated cardiomyopathy. Am J Cardiol 1985; 55:471-75
18. Wilson AC, Zhong-Hua L, Kostis JB. Effect of beta blockers in patients with low ejection fraction [abstract]. Circulation 1995; 92(suppl):I-331
19. Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure: US Carvedilol Heart Failure Study Group. N Engl J Med 1996; 334:1349-55
20. Bristow MB, Gilbert EM, Abraham WT, et al. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. Circulation 1996; 94:2807-16
21. Colucci WS, Packer M, Bristow MR, et al. Carvedilol inhibits clinical progression in patients with mild heart failure. Circulation 1996; 94:2800-06
22. Alderman J, Grassman W. Are beta-adrenergic-blocking drugs useful in the treatment of dilated cardiomyopathy? Circulation 1985; 71:854-57
23. Packer DL, Bardy DA, Gallagher JJ. Tachycardia-induced cardiomyopathy. J Am Coll Cardiol 1984; 3:521-26
24. McDonald CD, Burch CE. Prolonged bedrest in idiopathic cardiomyopathy. Am J Med 1972; 52:41-50
25. Krukemyer JJ. Use of beta-adrenergic blocking agents in congestive heart failure. Clin Pharm 1990; 9:853-63
26. Haber HL, Simek L, Bergin JD, et al. The beta-adrenergic system supports systolic function but not diastolic compliance in congestive heart failure [abstract]. Circulation 1991; 84(suppl):II-469
27. Bennett SK, Fisher ML, Krichten CM, et al. Benefit of beta blockers in patients with ischemic cardiomyopathy does not correlate with change in heart rate [abstract]. Circulation 1994; 90(suppl):I-544
28. Bashir Y, McKenna WJ, Camm AJ. Beta blockers and the failing heart: is it time for a U-turn? Br Heart J 1993; 70:8-12
29. Francis G. Comparison of neuroendocrine activity in patients with left ventricular dysfunction with or without congestive heart failure (SOLVD). Circulation 1990; 82:1724-29
30. Kabour A, Henegar JR, Janicki JS. Ability of beta blocker to prevent angiotensin II related myocyte necrosis [abstract]. Circulation 1994; 90(suppl):I-320
31. Fleckenstein A, Janke J, Doring HJ, et al. Calcium overload as the determinant factor in the production of catecholamine-induced myocardial lesions. Recent Adv Study Cardiac Struct Metab 1973; 2:455-68
32. Shanes JG. Beta-blockade - rational or irrational therapy for congestive heart failure? Circulation 1987; 76:971-72
33. Opie LH. Angiotensin converting inhibitors. 2nd ed. New York: Wiley-Liss. 1996: 2-9
34. Sackner-Bernstein J, Horn EM, Penn J, et al. Which component of the heta-adrenergic pathway best reflects the hemodynamic and clinical response to long-term beta blockade in chronic heart failure? [abstract]. Circulation 1991: 84 (suppl):II-469
35. Limas CJ, Boudoulas H, Limas C, et al. Anti-beta-receptor antibodies in familial cardiomyopathy [abstract]. Circulation 1991; 84(suppl):II-394
36. Matsui S, Fu L-X, Fukuoka T, et al. Autoantibodies against G-protein coupled receptors in patients with dilated cardiomyopathy [abstract]. Circulation 1994: 90(suppl):I-67
37. Goldenberg IF, Limas CJ. Inhibition by serum of dihydroalprenolol binding to cardiac beta-receptors in patients with heart failure [abstract]. J Am Coll Cardiol 1986; 7:94A
38. Daul A, Wojcek M, Brodde O-E. Chronic beta-adrenoceptor antagonist treatment sensitizes beta 2 adrenoceptor mediated chronotropic responses to isopreualine in humans [abstract]. Circulation 1991; 84(suppl):II-259
39. Gilbert EM, Olsen SL, Mealey P, Is beta-receptor upregulation necessary for improved LV function in dilated cardiomyopathy? [abstract]. Circulation 1991; 94(suppl):II-469
40. Beta-Blocker Heart Attack Research. A randomized trial of propranolol in patients with acute myocardial infarction: I. Mortality results. JAMA 1982; 247:1707-14
41. Hall S, Cigarroa C, Marcoux L, et al. Time course of left ventricular function improvement in patients with congestive heart failure treated with beta-adrenergic blockade [abstract]. Circulation 1990; 94(suppl):I-543
42. Distler A, Keim HJ. Sympathetic responsiveness and antihypertensive effect of beta blockade. Am J Med 1978; 64:446-51
43. Sackner-Bernstein J, Krum H, Goldsmith HL, et al. Should worsening heart failure early after initiation of beta-blocker therapy for chronic heart failure preclude long-term treatment? [abstract]. Circulation 1995; 92(suppl):I-395
44. White M, Michael E, Gilbert JA, et al. Do beta-blocking agents improve left ventricular function in subjects with ischemic dilated cardiomyopathy? [abstract]. J Am Coll Cardiol 1993; 21:115A
45. Fisher ML, Gottlieb SS, Plotnick GD, et al. Beneficial effects of metoprolol in heart failure associated with coronary artery disease. J Am Coll Cardiol 1994; 23:943-50
46. Maisel AS. Severe left ventricular dysfunction in the setting of myocardial ischemia: beneficial effects of titrating metoprolol dose [abstract]. Circulation 1994; 90(suppl):I-604
47. Olsen SL, Gilbert EM, Renlund DG, et al. Carvedilol improves left ventricular function and symptoms in chronic heart failure. J Am Coll Cardiol 1995; 25:1225-31
48. Australia-New Zealand Heart Failure Research Collaborative Group. Effects of carvedilol, a vasodilator-beta-blocker, in patients with congestive heart failure due to ischemic heart disease. Circulation 1995; 92:212-18
49. Woodley SL, Gilbert RM, Anderson JL, et al. Beta-blockade with bucindolol in heart failure caused by ischemic versus idiooathic dilated cardiomyopathy. Circulation 1991; 84:2426-41
50. Wisebaugh T, Katz I, Davis J, et al. Long-term (3-month) effect of a new beta-blocker (nebivolol) on cardiac performance in dilated cardiomyopathy. J Am Coll Cardiol 1993; 21:1094-1100
51. Valantine HA, Billingham ME, Heilbrunn SM, et al. Response to beta blockers in dilated cardiomyopathy predicted by myocardial biopsy [abstract]. Circulation 1995; 74(suppl): II-309
52. Yamada T, Fukunami M, Olmori M, et al. Which subgroup of patients with dilated cardiomyopathy would benefit from long-term beta-blocker therapy? a histologic viewpoint. J Am Coll Cardiol 1993; 21:628-33
53. Yamada T, Abe Y, Fukunami M, et al. Could effectiveness of long term β-blocker therapy for dilated cardiomyopathy be predicted by signal-averaged electrocardiography? [abstract]. Circulation 1995; 92(suppl):I-73
54. Schwartz BM, Sackner-Bernstein J, Penn J, et al. Which patients with chronic heart failure are most likely to show hemodynamic and functional improvement following long term beta-blockade? [abstract]. J Am Coll Cardiol 1992; 19:341A
55. Colm JN, Johnson G, Ziesche S, et al. A comparison of enalapril with hydralizing-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991; 325:303-10
56. Newton GE, Tong JH, Schofield AM, et al. Digoxin reduces cardiac sympathetic activity in severe congestive heart failure. J Am Coll Cardiol 1996; 28:155-61
57. Naoki I, Kashiki M, Suematsu M, et al. Chronic digoxin administration decreased beta-adrenocepter density in right heart failure [abstract]. Circulation 1991; 84(suppl):II-259
58. Horn EM, Corwin SJ, Steinberg SF, et al. Reduced lymphocyte stimulatory guanine nucleotide regulaton protein in beta-adrenergic receptors in congestive heart failure and reversal with angiotensin converting enzyme inhibitor therapy. Circulation 1988; 78:1373-79
59. Binkley PF, Lewe RF, Lima JJ, et al. Hemodynamic-inotropic response to beta-blocker with intrinsic sympathomimetic activity in patients with congestive cardiomyopathy. Circulation 1986; 74:1390-98
60. Gilbert EM, Anderson JL, Deitchman D, et al. Long-term beta-blocker vasodilator therapy improves cardiac function in idiopathic dilated cardiomyopathy: a double-blind, randomized study of bucindolol versus placebo. Am J Med 1990; 88:223-29
61. Bristow MR, O'Connell JB, Gilbert KM, et al. Dose-response of chronic beta blocker treatment in heart failure from either idiopathic dilated or ischemic cardiomyopathy, Circulation 1994; 89:1632-42
62. Heesch CM, Marcoux L, Hatfield B, et al. Hemodynamic and energetic comparison of bucindolol and metoprolol for the treatment of congestive heart failure. Am J Cardiol 1995; 75:360-64
63. Waagstein F, Caidahl K, Wallentin I, et al. Long-term beta-blockade in dilated cardiomyopathy. Circulation 1989; 80:551-63
64. Sung CP, Eichman C, Arleth AJ, et al. Carvedilol, a vascular protective agent, inhibits MAP kinase and cell cycle progression in vascular smooth muscle cells [abstract]. Circulation 1995; 92(suppl):1-297
65. Gillbert EM, Abraham WT, Olsen S, et al. Comparative hemodynamic left ventricular, functional, and antiadrenergic effects of chronic treatment with metoprolol versus carvedilol in the failing heart. Circulation 1996; 94:2817-25
66. Olsson G, Wikstrand J, Warnold I, et al. Metoprolol-induced reduction in post-infarction mortality: pooled results from five double-blind randomiced trials. Eur Heart J 1992; 13: 28-32